Abstracts tagged "B cells"

Abstract Number: 762 • 2016 ACR/ARHP Annual Meeting
Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy¹, Lina Martínez-Estupiñán², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College Hospital, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE). Hypogammaglobulinemia can be…
Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Megan Forney¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Orthopedics, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
Abstract Number: 2430 • 2016 ACR/ARHP Annual Meeting
Mutations in the Tyrosine-Protein Kinase Lyn Cause an Early-Onset Neutrophilic Vasculitis Syndrome
Adriana Almeida de Jesus¹, Gina A. Montealegre¹, Helen Freeman², Neil Martin³, Ebun Omoyinmi⁴, Bernadette Marrero¹, Katherine R. Calvo⁵, Chyi-Chia Richard Lee⁶, April D. Brundidge⁷, David Kleiner⁸, Stephen Hewitt⁸, Dawn C. Chapelle⁷, Yan Huang¹, Nirali Shah⁸, Stephen Brooks⁷, Eric Meffre⁹, Paul Brogan¹⁰, Hyesun Kuehn¹¹, Sergio Rosenzweig¹², Melinda Merchant⁸, Zuoming Deng⁷, Susan Moir¹³ and Raphaela Goldbach-Mansky¹⁴, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²Raigmore Hospital, Inverness, United Kingdom, ³Royal Hospital for Children, Glasgow, United Kingdom, ⁴University College London Institute of Child Health, London, United Kingdom, ⁵Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, ⁶Dermatopathology Section, Laboratory of Pathology, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD, ⁸National Cancer Institute, NIH, Bethesda, MD, ⁹Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ¹⁰UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, ¹²Department of Laboratory Medicine/NIH, Bethesda, MD, ¹³National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁴Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Tyrosine-protein kinase Lyn is a Src-family tyrosine kinase expressed by hematopoietic and non-hematopoietic cell types. Phosphorylation of a tyrosine residue at position 508 renders…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 1097 • 2015 ACR/ARHP Annual Meeting
Pre-Clinical Development of a Novel, Potent and Selective BTK Inhibitor for Autoimmune Disease and Inflammation Including Arthritis
Stephen Morris, Alain Laurent, Lori Jerome, Alain Boudreault, Helen Ashdown, Yannick Rose, Patrick Bureau, Shou-Yun Yin, Patrick Cleroux, Delphine Labit, Nicholas Henry, Marie-Noelle Tremblay, Marlyna Guerard, Emilie Dumas Bérubé and Kosta Spathis, Pharmascience Inc., Ville St-Laurent, QC, Canada
Background/Purpose: Bruton’s tyrosine kinase (BTK) is an important component of B cell and Fc receptor signaling and has been shown to be critical for B-cell…
Abstract Number: 1123 • 2015 ACR/ARHP Annual Meeting
Regulatory B Cells Regulate Skin and Lung Fibrosis and Immunological Abnormalities in a Topoisomerase I and Complete Freund’s Adjuvant-Induced Scleroderma Model Via an Antigen-Specific Manner
Ayumi Yoshizaki¹, Takashi Taniguchi¹, Kouki Nakamura¹, Ryosuke Saigusa¹, Takashi Yamashita¹, Takehiro Takahashi¹, Tetsuo Toyama¹, Yohei Ichimura¹, Yoshihide Asano² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Immune cells play a critical role in systemic sclerosis (SSc). B cells have more functions than producing antibodies, including antigen-presentation, various cytokine production, and…
Abstract Number: 3105 • 2015 ACR/ARHP Annual Meeting
The RA Immune System Recreated in Immunodeficient Mice By Thymic Differentiation from RA Patients’ Hematopoietic Stem Cells Exhibits Marked CD4 T Cell Activation and Differentiation
Robert Winchester¹, Chiara Borsotti², Nichole Danzl², Jon Giles³, Joan M. Bathon⁴ and Megan Sykes², ¹Dept of Pediatrics & Medicine, Columbia University, New York, NY, ²Medicine, Columbia University, New York, NY, ³Rheumatology, Columbia University Medical Center, NY, NY, ⁴Medicine, Columbia University, College, New York, NY
Background/Purpose: We recently reported an advance in modeling the human immune system in mice, (Kalscheuer et al. Sci Transl Med 2012) involving maturation of patient…
Abstract Number: 1099 • 2015 ACR/ARHP Annual Meeting
Single Cell RNA-Seq Analysis of Citrullinated Alpha-Enolase Peptide-Specific B Cells in RA
Yogita Ghodke-Puranik¹, Na Zhang², Jessica M. Dorschner¹, Anna Shmagel³, Zhongbo Jin¹, Philip Titcombe⁴, Timothy B. Niewold¹ and Daniel Mueller⁵, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Medicine, University of Minnesota Medical School, Minneapolis, MN, ³Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁴University of Minnesota Medical School, Minneapolis, MN, ⁵Medicine/Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The high prevalence of citrullinated protein antibodies and improvement following rituximab anti-CD20 therapy both suggest that B cells are important in the pathogenesis of…
Abstract Number: 1124 • 2015 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase Levels Are Increased in B Cells from Patients with Primary Sjögren’s Syndrome
Odilia B.J. Corneth¹, Gwenny Verstappen², Marjolein de Bruijn¹, Erlin A. Haacke³, Arjan Vissink⁴, Hendrika Bootsma⁵, Frans G.M. Kroese² and Rudi W. Hendriks¹, ¹Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Upon B cell receptor stimulation, B cells increase protein expression levels of the key downstream signaling molecule Bruton’s tyrosine kinase (BTK). BTK-transgenic mice that…
Abstract Number: 3152 • 2015 ACR/ARHP Annual Meeting
The IL-21 Signaling Pathway Is Enhanced in RA B Cells and Has the Potential to Alter Development and Cytokine Production in RA B Cells
Jane H. Buckner¹ and Elizabeth Samuelson², ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Translational Research, Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: B cells have been implicated in the development of rheumatoid arthritis (RA) based on their production of autoantibodies and cytokines as well as the…
Abstract Number: 1100 • 2015 ACR/ARHP Annual Meeting
Citrullinated Antigen-Specific B Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis: Identification and Phenotypic Characterization
Priscilla Kerkman¹, Ellen I.H. van der Voort¹, Arnaud Zaldumbide², Emeline Fabre¹, Yoann Rombouts¹, Theo Rispens³, Gertjan Wolbink⁴, Rob Hoeben², Hergen Spits⁵, Dominique Baeten⁶, T. W. J. Huizinga¹, René E. M. Toes¹ and Hans Ulrich Scherer¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands, ³Sanquin Research, Amsterdam, Netherlands, ⁴Immunopathology, Sanquin Research, Amsterdam, Netherlands, ⁵Department of Cell Biology and Histology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁶Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of anti-citrullinated protein antibodies (ACPA) in the majority of patients. ACPA represent highly disease-specific biomarkers that…
Abstract Number: 1249 • 2015 ACR/ARHP Annual Meeting
Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells
Carolina Duarte¹, Lora Boteva², Timothy Vyse¹ and Michelle Fernando¹, ¹Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, ²MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic autoimmune disease characterized by autoantibody production and up-regulation of type 1 interferons (IFNs). The strongest genetic association…
Abstract Number: 3153 • 2015 ACR/ARHP Annual Meeting
Microrna-155/PU.1 Axis As an Epigenetic Regulator of B-Cells in Rheumatoid Arthritis
Stefano Alivernini¹, Barbara Tolusso¹, Mariola Kurowska-Stolarska², Roberta Benvenuto³, Antonella Mangoni³, Silvia Canestri¹, Luca Petricca¹, Anna Laura Fedele¹, Maria Rita Gigante¹, Clara Di Mario¹, Elisa Gremese¹, Iain B. McInnes² and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Division of Pathology - Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: MicroRNA-155(miR-155) has been shown to be a key regulator of B cell biology by PU.1 regulation. However, the role of miR-155 in the activation…
Abstract Number: 1102 • 2015 ACR/ARHP Annual Meeting
CD19+CD24-CD38hi B-Cell Subset: A Potential Biomarker for IgG4-Related Disease
Wen Zhang^1,2, Wei Lin³, Yu Chen⁴, Yunjiao Yang⁴, Hua Chen⁴, QingJun Wu⁴, Yunyun Fei⁴, Chaojun Hu⁴, Yongzhe Li³, Xuan Zhang³, Yan Zhao⁴, Fengchun Zhang³, Xiaofeng Zeng⁴ and Peter E. Lipsky⁵, ¹Rheuamtology, Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Rheumatology, Peking Union Medical College Hospital, Beijing, China, ⁵Bldg 10 Rm 6d47c, National Institutes of Health, Bethesda, MD
Background/Purpose: To investigate a B-cell subpopulation, exhibiting CD19+CD24-CD38hi phenotype, can be a biomarker for diagnosis and disease activity in IgG4 related disease (IgG4-RD). Methods: Circulating…
Abstract Number: 1380 • 2015 ACR/ARHP Annual Meeting
Characterization of Lymphocytes Subsets in Peripheral Blood of Untreated IgG4-Related Disease Patients
Aurélie Grados¹, Mikael Ebbo¹, Christelle Piperoglou², Matthieu Groh³, Alexis Regent⁴, Maxime Samson⁵, Benjamin Terrier⁶, Nathalie Morel⁷, Sylvain Audia⁵, Francois Maurier⁸, Julie Graveleau⁹, Mohamed Hamidou¹⁰, Amandine Forestier¹¹, Sylvain Palat¹², Emanuelle Bernit¹, Gilles Kaplanski¹³, Frederique Retornaz¹⁴, Bernard Bonotte⁵, Catherine Farnarier¹⁵, Jean-Robert Harle¹⁶, Nathalie Costedoat-Chalumeau⁷, Frederic Vely¹⁷ and Nicolas Schleinitz¹, ¹Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ²Immunology, CIML, AP-HM, Marseille, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁴Service de médecine interne, Hôpital Cochin, Paris, France, ⁵Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁶Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Medecine Interne Hotel Dieu Nantes, Nantes, France, ¹⁰Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹¹Internal Medicine, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France, ¹²Service de Medecine Interne, CHU limoges, Limoges, France, ¹³Internal Medicine hopital conception, Aix-Marseille Université, Marseille, France, ¹⁴Conseil General 13 cellule recherche, Marseille, France, ¹⁵Laboratoire d'immunologie, Hopital de la Conception, Marseille, France, ¹⁶Internal Medicine, Aix-Marseille Université, APHM, Marseille, France, ¹⁷CIML, Laboratoire d'Immunologie Conception AP-HM, Aix-Marseille université, Marseille, France
Background/Purpose: IgG4-related disease (IgG4-RD) is associated with characteristic pathological changes including lymphoplasmocytic infiltration with abundant IgG4 positive plasma cells, storiform fibrosis and obliterative phlebitis. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].